AZNCF - Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
2024-05-23 12:36:52 ET
Summary
- Lantheus Holdings, Inc. excels in radiopharmaceuticals, with PYLARIFY's dominance in PSMA PET imaging.
- The market for radiopharmaceuticals is expanding beyond all expectations by both industry experts and the company's management.
- Lantheus is actively expanding its pipeline by making strategic investments backed by a robust balance sheet.
I first heard about Lantheus Holdings, Inc. (LNTH) , one of the leaders in the radiopharmaceutical industry, in May 2021 after the company crushed their Q2 earnings report and the stock ripped 48% higher over the next month. LNTH stayed on my watch list for a year, then after a strong CY2022 Q1 earnings report, I decided to take a small starter position.
When I published my deep dive on Lantheus in May 2022, the company was run by Mary Anne Heino, who had been at the helm since the company went public in 2015. It was Mary Anne who took Lantheus from a ~$200 million company to a ~$4 billion company and a leader in the field of diagnostic imaging....
Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus